Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. Robert Perneczky
Division of Mental Health in Older Adults and Alzheimer Therapy and Research Center, Ludwig Maximillians University Munich, Munich, Germany
Robert Perneczky is Professor of Psychiatry at Ludwig Maximilians-University (LMU) Munich and director of the Division of Old Age Psychiatry and the Alzheimer’s Research and Therapy Centre at the LMU University Hospital. He has over 20 years of experience with translational dementia research, focusing on imaging and fluid biomarkers, amongst other areas of interest, and has published over 200 peer-reviewed articles.
Prof. Robert Perneczky has received advisory boards and speaker fees from AstraZeneca, Biogen, EISAI, Eli Lilly, Grifols, Janssen-Cilag, Novo Nordisk, Roche, Schwabe and Tabuk.
Prof. Sylvain Lehmann
University Hospital of Montpellier, Montpellier, France; Institute of Neurosciences and the Center of Excellence in Neurodegenerative Diseases, Montpellier, France
Sylvain Lehmann is head of the Montpellier Center of Excellence in Neurodegenerative Diseases and the Director of the Institute for Neurosciences of Montpellier (INM). His interests include various aspects of neurodegenerative disorders including therapy, diagnosis, pathophysiology and clinical proteomics. He is an author of 250 peer-reviewed publications.
Prof. Sylvain Lehmann has received consultancy, training, symposium and collaboration fees from AbbVie, Biogen, Eli Lilly, Fujirebio, Quanterix, Roche Diagnositics, Shimadzu and Spectrum
Prof. Pablo Martinez-Lage
Center for Research and Advanced Therapies of the Foundation CITA-alzhiemer Fundazioa, San Sebastian, Spain
Pablo Martinez-Lage is director of the Neurology area at the Center for Research and Advanced Therapies of the Fundacion CITA-alzheimer Fundazioa in San Sebastian. His main research interests include the neuroimaging, neuropsychological and clinical characterization of pre-clinical and early Alzheimer’s disease, in addition to mild cognitive impairment, vascular dementia, focal atrophies and frontotemporal dementias. He has published over 80 peer-reviewed articles.
Prof. Pablo Martinez-Lage has received advisory board and speaker fees from Pfizer, Novartis, Lundbeck and Janssen-Cilage; Speaker fees from Andromaco Grünenthal, Eli Lilly and Esteve.
